Alibaba Was Not the Only IPO This Week

Investing

Published: September 19, 2014 9:45 am

Last Updated: April 27, 2020 3:33 pm

Source: Thinkstock

What may be the world’s largest-ever initial public offering (IPO) is about to begin trading Friday, and the anticipation might suck all the air out of the IPO room. When Alibaba Group Holding Ltd. (NYSE: BABA) begins trading this morning even the vote rejecting independence in Scotland will have to fight for headline space.

Speaking of overlooked, there were six other IPOs scheduled to begin trading this week. Wisely none chose to go out on the same day as Alibaba.

The IPO week started on Wednesday with Civitas Solutions Inc. (NYSE: CIVI), which claims to be the country’s leading provider of in-home and community-based health services. Shares priced at $17, well below the expected range of $20 to $23, and dipped to $16.16 on its opening day. Shares closed at $16.61 on Thursday.

A clinical-stage biopharmaceutical company developing treatments for prostate cancer and other hormonally driven diseases, Tokai Pharmaceuticals Inc. (NASDAQ: TKAI) also began trading on Wednesday. The company upsized its offering from 5.4 million shares to 6.5 million and priced the shares at $15, the top of the expected range. The stock jumped above $28 before closing its first trading day at $23.76. Shares closed Thursday at $19.77 and traded down another 3.6% in Friday’s premarket session to $19.05.

Foamix Ltd. (NASDAQ: FOMX) is an Israel-based clinical-stage pharmaceutical firm developing a foam treatment for acne, impetigo and other skin conditions. The company upsized the number of shares on offer from 5.9 million to 6.7 million, but priced the shares at $6, way below the expected range of $10 to $12. After popping to $11 shortly after trading began on Thursday, shares closed at $6.22, and they traded at $6.14 in Friday’s premarket.

Dutch biopharma firm ProQR Therapeutics B.V. (NASDAQ: PRQR) is developing RNA-based therapeutics for treating severe genetic disorders. ProQR also upsized the number of shares it offered on Thursday, from 6.3 million to 7.5 million, and priced the shares at $13, the top end of its expected range. Shares peaked at $21.87 before closing at $14.73. The stock was trading down about 2.2% in Friday’s premarket session.

Two other IPOs scheduled for this week have been delayed: Viking Therapeutics and rEVO Biologics are both currently listed as day-to-day regarding pricing and trading dates.

ALSO READ: Six Stocks Portfolio Managers Are Selling to Fund New Alibaba Stakes

Smart Investors Are Quietly Loading Up on These “Dividend Legends” (Sponsored)

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.